Mizuho views the selloff yesterday in shares of Encompass Health (EHC) following the New York Times report questioning the quality of the company’s care as overdone. The article “presents a selective one-sided perspective,” the analyst tells investors in a research note. Mizuho says the ten patients mentioned in the article represent less than 0.001% of all Encompass patients since 2021. The firm believes the company’s earnings viability remains high and reiterates an Outperform rating on the name. It would buy the stock on the weakness.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EHC:
- Encompass Health: Strong Growth Prospects and Industry Position Justify Buy Rating
- Encompass drops 10% to $107.44 after NY Times report on rehab centers
- Errors at rehab hospitals go ‘unpenalized and undisclosed,’ NY Times says
- Encompass selloff on report a buying opportunity, says KeyBanc
- Encompass Health Highlights Financial Measures in New Book